Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceuticals Ltd. is a subsidiary of Galmed International Ltd.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-3693-8448
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.09 million
Profitability
Miscellaneous
Employees17
OptionableOptionable
Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions
What is Galmed Pharmaceuticals' stock symbol?
Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."
How were Galmed Pharmaceuticals' earnings last quarter?
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) posted its quarterly earnings data on Monday, November, 5th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.09. The biopharmaceutical company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $0.30 million. Galmed Pharmaceuticals had a negative return on equity of 18.55% and a negative net margin of 423.62%. View Galmed Pharmaceuticals' Earnings History.
When is Galmed Pharmaceuticals' next earnings date?
What price target have analysts set for GLMD?
7 brokerages have issued 1-year price objectives for Galmed Pharmaceuticals' shares. Their forecasts range from $20.00 to $59.00. On average, they anticipate Galmed Pharmaceuticals' share price to reach $35.75 in the next year. This suggests a possible upside of 320.6% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals.
What is the consensus analysts' recommendation for Galmed Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals.
Has Galmed Pharmaceuticals been receiving favorable news coverage?
Media stories about GLMD stock have been trending neutral recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Galmed Pharmaceuticals earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next several days.
Who are some of Galmed Pharmaceuticals' key competitors?
Some companies that are related to Galmed Pharmaceuticals include Assembly Biosciences (ASMB), Flexion Therapeutics (FLXN), Arvinas (ARVN), Collegium Pharmaceutical (COLL), Zymeworks (ZYME), Innate Pharma (IPHYF), NuCana (NCNA), Obseva (OBSV), Forty Seven (FTSV), Akorn (AKRX), Prothena (PRTA), Theratechnologies (THERF), Eidos Therapeutics (EIDX), Corium International (CORI) and Corbus Pharmaceuticals (CRBP).
Who are Galmed Pharmaceuticals' key executives?
Galmed Pharmaceuticals' management team includes the folowing people:
- Mr. Yohai Stenzler, CFO & Controller (Age 35)
- Mr. Guy Nehemya, VP of Operations (Age 33)
- Dr. Liat Hayardeny, Chief Scientific Officer (Age 51)
- Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 35)
- Dr. Tali Gorfine, Chief Medical Officer (Age 48)
Who are Galmed Pharmaceuticals' major shareholders?
Galmed Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include First Midwest Bank Trust Division (1.35%).
Which major investors are buying Galmed Pharmaceuticals stock?
GLMD stock was bought by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division.
How do I buy shares of Galmed Pharmaceuticals?
Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Galmed Pharmaceuticals' stock price today?
One share of GLMD stock can currently be purchased for approximately $8.50.
How big of a company is Galmed Pharmaceuticals?
Galmed Pharmaceuticals has a market capitalization of $136.17 million and generates $1.09 million in revenue each year. The biopharmaceutical company earns $-12,290,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.
What is Galmed Pharmaceuticals' official website?
How can I contact Galmed Pharmaceuticals?
Galmed Pharmaceuticals' mailing address is 16 ZE`EV TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.
MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
